Cargando…
The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
INTRODUCTION: Major depressive disorder (MDD) is a common affective disorder. Currently established pharmacotherapies lack rapid clinical response, thereby limiting their ability to bring instant relief to patients. A series of clinical trials has demonstrated the antidepressant effects of scopolami...
Autores principales: | Zhou, Jingjing, Yang, Jian, Zhu, Xuequan, Zghoul, Tarek, Feng, Lei, Chen, Runsen, Wang, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331769/ https://www.ncbi.nlm.nih.gov/pubmed/32655854 http://dx.doi.org/10.1177/2045125320938556 |
Ejemplares similares
-
Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis
por: Wang, Xiao, et al.
Publicado: (2023) -
Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019) -
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study
por: Zhou, Jingjing, et al.
Publicado: (2021) -
A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
por: Chen, Joseph C. C., et al.
Publicado: (2020) -
Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial
por: Miravalles, Cerena, et al.
Publicado: (2022)